Anna MacDonald profile page

Technology Networks spoke with Dr. Ben Hindson, co-founder and chief scientific officer of 10x Genomics, to learn more about the challenges of conducting single-cell analyses in space and how terrestrial single-cell methods will be adapted for use in space.

To learn how cell cultured human milk is produced and how it compares to mothers’ milk, Technology Networks spoke to Shayne Guiliano, CEO of 108Labs. In this interview, Shayne also highlights the impact that scaling up the technology will have and shares his thoughts on what could be in store for the future of cellular agriculture.

In this interview, Dr. George Emanuel discusses some of the most exciting findings from the Mouse Receptor Map and highlights how the datasets will benefit the Human Cell Atlas project.

To learn more about the causes and consequences of peripheral nerve damage and some of the solutions available to patients, Technology Networks spoke with Karen Zaderej, chief executive officer of Axogen.

Women’s Health Access Matters recently released The WHAM Report, outlining new research conducted by the RAND Corporation to study the impact of accelerating sex- and gender-based AD, heart and autoimmune research on women, their families and the economy. To learn more about the report, the recently released AD findings and their significance, we spoke to Carolee Lee, founder and CEO of WHAM.

Technology Networks recently had the pleasure of speaking with ImVitro’s CEO and founder, Dr Alexandra Boussommier-Calleja, to learn more about IVF and how artificial intelligence (AI) could help to address some of the challenges associated with the technique.

Many of us are familiar with the undesirable physical and mental effects of a disrupted sleep/wake cycle caused by traveling across multiple time zones or working irregular hours. A collaborative project designed to address these issues is working to develop a “living pharmacy” – a personalized, wireless and fully implantable device that can control the body’s circadian clock.

We spoke with Archie Cullen, senior vice president and head of bioscience solutions, Lonza. In this interview, Archie discusses the evolution of the Nucleofector® Technology, highlighting how it has supported and propelled basic and applied research. He also explores some of the most recent developments in the Nucleofector® Platform’s exciting journey.

Technology Networks recently spoke with Jeff Stevens, Psyched Wellness’s CEO, to learn more about muscimol, its therapeutic potential and how it compares to other psychedelics such as psilocybin.

In this interview, David E. Olson discusses the potential commercial, clinical and scientific implications of non-hallucinogenic psychedelic compounds.